2022, Number 4
<< Back Next >>
Enf Infec Microbiol 2022; 42 (4)
Invasive tracheobronchial aspergillosis in a patient with acute lymphoblastic leukemia (ALL) of PreB cells in late maintenance phase
González RLO, Jiménez HBA, Rodríguez VA, Santos HJE, Acosta RCQ, Contreras CTIF, Loaeza RRT
Language: Spanish
References: 28
Page: 185-188
PDF size: 182.77 Kb.
ABSTRACT
A high risk of invasive aspergillosis has been observed in patients with hemato-oncological pathologies. Although
chemotherapy schemes have decreased toxicity, there is still a high risk of immunosuppression.
Aspergillosis associated with tracheobronchial diseases includes saprophytic, allergic, and invasive tracheobronchial
aspergillosis (ATBI) forms. The incidence of ATBI is around 6.9%, with a lethality between 58 and 90%.
Currently, voriconazole is the first-line treatment; an alternative is isavuconazole.
We present the case of a patient with acute lymphoblastic leukemia (ALL), with recurrent episodes of pneumonia
manifested by hypoxemia and persistent fever, with a final diagnosis of invasive tracheobronchial aspergillosis.
REFERENCES
Routsi, C., Kaltsas, P., Bessis, E., Rontogianni, D., Kollias,S. y Roussos, C., “Airway obstruction and acuterespiratory failure due to Aspergillus tracheobronchitis”.Crit Care Med 2004; 32 (2): 580-582.
Alastruey, A., Mellado, E. y Cuenca, M., “Current sectionand species complex concepts in Aspergillus:recommendations for routine daily practice”. Ann N YAcad Sci, 2012; 1273: 18-24.
Mandell, G.L., Bennett, J.E. y Dolin, R., Enfermedadesinfecciosas: principios y práctica, 9ª ed., Barcelona, Elsevier,2020.
Kwon-Chung, K.J., “Aspergillus: diagnosis and descriptionof the genus”, en Vanden Bossche, H., Mackenzie,D.W.R. y Cauwenbergh, G. (eds.) Proceedings of theSecond International Symposium on Topics in Mycology,Amberes, Universidad de Amberes, 1987, pp. 11-21.
Krenke, R. y Grabczak, E.M., “Tracheobronchial manifestationsof Aspergillus infections”. Scientific WorldJournal 2011; 11: 2310-2329.
Denning, D.W., “Commentary: unusual manifestationsof aspergillosis”. Thorax, 1995; 50 (7): 812-813.
Kramer, M.R., Denning, D.W., Marshall, S.E. et al., “Ulcerativetracheobronchitis after lung transplantation: anew form of invasive aspergillosis”. Am Rev RespiratoryDis 1991; 144 (3 I): 552-556.
Denning, D.W., “Invasive aspergillosis”. Clin Infect Dis1998; 26 (4): 781-803.
Andresen, H., Venegas, P., Vega, C., Aravena, C. y Andresen,V. “Necrotizing tracheobronchial aspergillosis in an immunosuppressedpatient. Report of one case”, Rev Méd. Chile2015; 143 (4): 525-530.
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll,A.H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C.y Herbrecht, R., “ecil-6 guidelines for the treatment ofinvasive candidiasis, aspergillosis and mucormycosisin leukemia and hematopoietic stem cell transplant patients”.Haematologica 2017; 102 (3): 433-444.
Patterson, T.F., Thompson, G.R. 3rd, Denning, D.W., Fishman,J.A., Hadley, S., Herbrecht, R., et al. “PracticeGuidelines for the Diagnosis and Management of Aspergillosis:2016. Update by the Infectious DiseasesSociety of America”, Clin Infect Dis 2016; 63 (4): e1-e60.
Ullmann, A.J., Aguado, J.M., Arikan-Akdagli, S., Denning,D.W., Groll, A.H., Lagrou, K., et al. “Diagnosis and managementof Aspergillus diseases: executive summary ofthe 2017 escmid-ecmm-ers guideline”. Clin Microbiol Infect2018; 24 Suppl 1: e1-e38.
Warris, A., Lehrnbecher, T., Roilides, E., Castagnola, E.,Brüggemann, R.J.M, Groll, A.H., “escmid-ecmm guideline:diagnosis and management of invasive aspergillosis inneonates and children”. Clin Microbiol Infect, 2019; 25(9): 1096-1113. doi: 10.1016/j.cmi.2019.05.019. Epub 31de mayo de 2019. pmid: 31158517.
Fernández, A., Lewis, R.E. y Kontoyiannis, D.P., “Howlong do we need to treat an invasive mold disease inhematology patients? Factors influencing duration oftherapy and future questions”, Clin Infect Dis, 2020; 71(3): 685-692.
Davoudi, S., Anderlini, P., Fuller, G.N. y Kontoyiannis,D.P., “A long-term survivor of disseminated Aspergillusand mucorales infection: an instructive case”. Mycopathologia,2014; 178: 465-470.
Parekh, B.S., Ou, C.Y., Fonjungo, P.N., Kalou, M.B.,Rottinghaus, E., Puren, A. et al., “Diagnosis of humanimmunodeficiency virus. Infection”, Clin Microbiol Rev, 2018; 32 (1): e00064-18.
Instituto Nacional de Estadística y Geografía (inegi), “Estadísticasa propósito del Día Mundial de la Lucha Contrael vih/sida (1 de diciembre)”, Comunicado de Prensanúm. 698/21, 29 de noviembre de 2021, 5 pp.
Fanales-Belasio, E., Raimondo, M., Suligoi, B. y Buttò,S., “hiv virology and pathogenetic mechanisms of infection:a brief overview”. Ann Ist Super Sanita 2010; 46(1): 5-14.
Deeks, S.G., Overbaugh, J., Phillips, A. y Buchbinder, S.,“hiv infection”. Nat Rev Dis Primers 2015; 1: 15035.
Braun, D.L., Kouyos, R.D., Balmer, B., Grube, C., Weber,R. y Günthard, H.F., “Frequency and spectrum ofunexpected clinical manifestations of primary hiv-1 infection”.Clin Infect Dis, 2015; 61 (6): 1013-1021.
Zandman-Goddard, G. y Shoenfeld, Y., “hiv and autoimmunity”.Autoimmun Rev 2002; 1 (6): 329-337.
Muema, D.M., Akilimali, N.A., Ndumnego, O.C., Rasehlo,S.S., Durgiah, R., Ojwach, D.B.A., et al. “Associationbetween the cytokine storm, immune cell dynamics,and viral replicative capacity in hyperacute hiv infection”.bmc Med 2020; 18 (1): 81.
Kreuzer, K.A. y Rockstroh, J.K., “Pathogenesis and pathophysiologyof anemia in hiv infection”. Ann Hematol1997; 75 (5-6): 179-187.
Español, I., Muñiz-Díaz, E., Margall, N., Rabella, N., Sambeat,M.A., Hernández, A. et al., “Serum thrombopoietinlevels in thrombocytopenic and non-thrombocytopenicpatients with human immunodeficiency virus (hiv-1) infection”.Eur J Haematol, 1999; 63 (4): 245-250.
Bettaieb, A., Oksenhendler, E., Duedari, N. y Bierling, P.,“Cross-reactive antibodies between hiv-gp120 and plateletgpiiia (cd61) in hiv-related immune thrombocytopenicpurpura”. Clin Exp Immunol, 1996; 103 (1): 19-23.
Semple, J.W., Rebetz, J., Maouia, A. y Kapur, R., “An updateon the pathophysiology of immune thrombocytopenia”.Curr Opin Hematol 2020; 27 (6): 423-429.
Semple, J.W., “Immune pathophysiology of autoimmunethrombocytopenic purpura”. Blood Rev, 2002; 16 (1): 9-12.
Secretaría de Salud, Subsecretaría de Prevención yPromoción de la Salud, Dirección General de Epidemiología,Sistema de Vigilancia Epidemiológica, “Informehistórico Día Mundial vih 2021”.